Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
0.9800
+0.3180
+(48.04%)
At close: February 21 at 3:00:00 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Steven W. King | Chairman of the Board, President & CEO | 267.84k | -- | 1964 |
| Mr. Paul J. Lytle CPA | Executive VP, CFO, Secretary & Director | 295.53k | -- | 1968 |
| Mr. Joseph S. Shan M.P.H. | Head of Clinical Operations | -- | -- | 1973 |
| Dr. Marvin R. Garovoy M.D. | Head of Medical Immuno-Oncology | -- | -- | 1944 |
| Cyril Empig Ph.D. | Head of Vaccine Development | -- | -- | -- |
Mosaic ImmunoEngineering, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate is MIE-101 which is based on cowpea mosaic virus which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
Corporate Governance
Mosaic ImmunoEngineering, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 14, 2025 at 10:59 AM UTC - April 18, 2025 at 12:00 PM UTC
Mosaic ImmunoEngineering, Inc. Earnings Date
Recent Events
Related Tickers
OTLC Oncotelic Therapeutics, Inc.
0.0300
-13.04%
PMCB PharmaCyte Biotech, Inc.
1.7600
-2.76%
ENTX Entera Bio Ltd.
2.1000
-4.11%
CELZ Creative Medical Technology Holdings, Inc.
5.40
-9.85%
NWBO Northwest Biotherapeutics, Inc.
0.2500
+2.00%
CVM CEL-SCI Corporation
0.3960
-6.38%
VKTX Viking Therapeutics, Inc.
34.07
+7.71%